| Year |
Citation |
Score |
| 2023 |
Bahnassy S, Stires H, Jin L, Tam S, Mobin D, Balachandran M, Podar M, McCoy MD, Beckman RA, Riggins RB. Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. Endocrinology. 164. PMID 37897495 DOI: 10.1210/endocr/bqad159 |
0.387 |
|
| 2023 |
Olukoya AO, Stires H, Bahnassy S, Persaud S, Guerra Y, Ranjit S, Ma S, Cruz MI, Benitez C, Rozeboom AM, Ceuleers H, Berry DL, Jacobsen BM, Raj GV, Riggins RB. Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer. Journal of the Endocrine Society. 7: bvad117. PMID 37766843 DOI: 10.1210/jendso/bvad117 |
0.415 |
|
| 2023 |
Riggins RB, Ranjit S. Targeting the NAD+ Salvage Pathway: Synergistic Therapeutic Strategy for ER+ Metastatic Breast Cancer. Endocrinology. PMID 37738166 DOI: 10.1210/endocr/bqad140 |
0.343 |
|
| 2023 |
Bahnassy S, Stires H, Jin L, Tam S, Mobin D, Balachandran M, Podar M, McCoy MD, Beckman RA, Riggins RB. Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. Biorxiv : the Preprint Server For Biology. PMID 37662291 DOI: 10.1101/2023.08.21.554116 |
0.378 |
|
| 2023 |
Gaymon DO, Barndt R, Stires H, Riggins RB, Johnson MD. ROS is a master regulator of in vitro matriptase activation. Plos One. 18: e0267492. PMID 36716335 DOI: 10.1371/journal.pone.0267492 |
0.336 |
|
| 2020 |
Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, et al. Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1 mutant breast cancer. Cancer Research. PMID 33184106 DOI: 10.1158/0008-5472.CAN-20-1200 |
0.334 |
|
| 2020 |
Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack. Methods in Enzymology. 636: 299-322. PMID 32178823 DOI: 10.1016/Bs.Mie.2019.06.002 |
0.457 |
|
| 2020 |
Olukoya AO, Stires H, Guerra Y, Persaud S, Ma S, Raj GV, Riggins RB. SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.1086 |
0.526 |
|
| 2020 |
Boca S, Bhuvaneshwar K, Fernandez-Vega V, Kancherla J, Rao S, Madhavan S, Riggins R, Beckman RA, Corrada Bravo H, Scampavia L, Spicer T. Prioritizing targeted therapies in an evidence-based manner, integrating biological context and functional precision medicine. Journal of Clinical Oncology. 38: e14065-e14065. DOI: 10.1200/Jco.2020.38.15_Suppl.E14065 |
0.336 |
|
| 2019 |
Fernandez AI, Geng X, Chaldekas K, Harris B, Duttargi A, Berry VL, Berry DL, Mahajan A, Cavalli LR, Győrffy B, Tan M, Riggins RB. The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 31741180 DOI: 10.1007/S10549-019-05485-5 |
0.472 |
|
| 2019 |
Tiek DM, Khatib SA, Trepicchio CJ, Heckler MM, Divekar SD, Sarkaria JN, Glasgow E, Riggins RB. Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201901075R. PMID 31570001 DOI: 10.1096/Fj.201901075R |
0.311 |
|
| 2018 |
Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, Van Houten B, Oesterreich S. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Research : Bcr. 20: 106. PMID 30180878 DOI: 10.1186/S13058-018-1041-8 |
0.479 |
|
| 2018 |
Tiek DM, Rone JD, Graham GT, Pannkuk EL, Haddad BR, Riggins RB. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma. Scientific Reports. 8: 7222. PMID 29740146 DOI: 10.1038/S41598-018-25588-1 |
0.376 |
|
| 2018 |
Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, Pacini S, Cheema A, Varghese R, Ressom HW, Zhang Y, et al. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death and Differentiation. PMID 29651165 DOI: 10.1038/S41418-018-0101-Z |
0.392 |
|
| 2018 |
Fernandez A, Graham G, Győrffy B, Cavalli L, Mahajan A, Riggins R. Abstract P3-07-09: ERRβ copy number and expression in triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-07-09 |
0.503 |
|
| 2017 |
Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio-Protocol. 7. PMID 29250574 DOI: 10.21769/BioProtoc.2435 |
0.308 |
|
| 2017 |
Wathieu H, Issa NT, Fernandez AI, Mohandoss M, Tiek DM, Franke JL, Byers SW, Riggins RB, Dakshanamurthy S. Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. Oncotarget. 8: 92926-92942. PMID 29190967 DOI: 10.18632/Oncotarget.21669 |
0.397 |
|
| 2017 |
Stires H, Heckler MM, Fu X, Li Z, Grasso CS, Quist MJ, Lewis JA, Klimach U, Zwart A, Mahajan A, Győrffy B, Cavalli LR, Riggins RB. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities. Molecular and Cellular Endocrinology. PMID 28935545 DOI: 10.1016/J.Mce.2017.09.024 |
0.507 |
|
| 2017 |
ElChaarani B, Stires H, Pohlmann PR, Riggins R. Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer. Journal of Clinical Oncology. 35: e12520-e12520. DOI: 10.1200/Jco.2017.35.15_Suppl.E12520 |
0.513 |
|
| 2017 |
Clarke R, Hu R, Warri A, Jin L, Zwart A, Riggins R, Fang H. Abstract P3-04-12: Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogen via NFkappaB signaling Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-04-12 |
0.536 |
|
| 2017 |
Fernandez AI, Graham G, Győrffy B, Cavalli L, Riggins RB. Abstract 4131: ERRβ: Validating a novel target for triple negative breast cancer Cancer Epidemiology, Biomarkers & Prevention. 77: 4131-4131. DOI: 10.1158/1538-7445.Am2017-4131 |
0.423 |
|
| 2017 |
Stires H, Riggins RB. Abstract 3605: The role of androgen receptor in invasive lobular breast carcinoma Endocrinology. 77: 3605-3605. DOI: 10.1158/1538-7445.Am2017-3605 |
0.38 |
|
| 2016 |
Divekar SD, Tiek DM, Fernandez A, Riggins RB. Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor renaissance? Nuclear Receptor Signaling. 14: e002. PMID 27507929 DOI: 10.1621/Nrs.14002 |
0.306 |
|
| 2016 |
Heckler MM, Zeleke TZ, Divekar SD, Fernandez AI, Tiek DM, Woodrick J, Farzanegan A, Roy R, Üren A, Mueller SC, Riggins RB. Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer. Oncotarget. PMID 27363015 DOI: 10.18632/Oncotarget.9719 |
0.493 |
|
| 2015 |
Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, et al. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene. PMID 26165839 DOI: 10.1038/Onc.2015.226 |
0.528 |
|
| 2015 |
Madhavan S, Gusev Y, Singh S, Riggins RB. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer. Journal of Experimental & Clinical Cancer Research : Cr. 34: 45. PMID 25971350 DOI: 10.1186/S13046-015-0150-9 |
0.511 |
|
| 2015 |
Schwartz-Roberts JL, Cook KL, Chen C, Shajahan-Haq AN, Axelrod M, Wärri A, Riggins RB, Jin L, Haddad BR, Kallakury BV, Baumann WT, Clarke R. Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate. Cancer Research. 75: 1046-55. PMID 25576084 DOI: 10.1158/0008-5472.Can-14-1851 |
0.508 |
|
| 2015 |
Heckler MM, Riggins RB. ERRβ splice variants differentially regulate cell cycle progression. Cell Cycle (Georgetown, Tex.). 14: 31-45. PMID 25496115 DOI: 10.4161/15384101.2014.972886 |
0.351 |
|
| 2015 |
Hu R, Warri A, Jin L, Zwart A, Riggins RB, Fang HB, Clarke R. NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Molecular and Cellular Biology. 35: 379-90. PMID 25368386 DOI: 10.1128/Mcb.00847-14 |
0.512 |
|
| 2015 |
Zhang Y, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, et al. Abstract 1716: Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation Cancer Research. 75: 1716-1716. DOI: 10.1158/1538-7445.Am2015-1716 |
0.537 |
|
| 2014 |
Riggins RB. The pERK of being a target: Kinase regulation of the orphan nuclear receptor ERRγ. Receptors & Clinical Investigation. 1. PMID 26005698 DOI: 10.14800/Rci.207 |
0.436 |
|
| 2014 |
Heckler MM, Thakor H, Schafer CC, Riggins RB. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer. The Febs Journal. 281: 2431-42. PMID 24684682 DOI: 10.1111/Febs.12797 |
0.543 |
|
| 2013 |
Chen X, Xuan J, Wang C, Shajahan AN, Riggins RB, Clarke R. Reconstruction of transcriptional regulatory networks by stability-based network component analysis. Ieee/Acm Transactions On Computational Biology and Bioinformatics / Ieee, Acm. 10: 1347-58. PMID 24407294 DOI: 10.1109/Tcbb.2012.146 |
0.329 |
|
| 2013 |
Gusev Y, Riggins RB, Bhuvaneshwar K, Gauba R, Sheahan L, Clarke R, Madhavan S. In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. Cancer Informatics. 12: 31-51. PMID 23470717 DOI: 10.4137/Cin.S10329 |
0.426 |
|
| 2013 |
Chen L, Xuan J, Riggins RB, Wang Y, Clarke R. Identifying protein interaction subnetworks by a bagging Markov random field-based method. Nucleic Acids Research. 41: e42. PMID 23161673 DOI: 10.1093/Nar/Gks951 |
0.41 |
|
| 2013 |
Riggins RB, Heckler MM, Thakor H, Schafer CC, Singh S, Tian Y, Gusev Y, Madhavan S, Wang Y. Abstract 3570: Phospho-dependent regulation of ERRγ expression, transcriptional activity, and Tamoxifen resistance in ER+ breast cancer. Cancer Research. 73: 3570-3570. DOI: 10.1158/1538-7445.Am2013-3570 |
0.56 |
|
| 2013 |
Heckler M, Albanese C, Riggins R. Abstract 3322: GW4716 selectively targets multiple p53 mutant cancer models. Cancer Research. 73: 3322-3322. DOI: 10.1158/1538-7445.Am2013-3322 |
0.366 |
|
| 2012 |
Yenugonda VM, Kong Y, Deb TB, Yang Y, Riggins RB, Brown ML. Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells. Cancer Biology & Therapy. 13: 925-34. PMID 22785207 DOI: 10.4161/Cbt.20845 |
0.478 |
|
| 2012 |
Gu J, Xuan J, Riggins RB, Chen L, Wang Y, Clarke R. Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic. Bioinformatics (Oxford, England). 28: 1990-7. PMID 22595208 DOI: 10.1093/Bioinformatics/Bts296 |
0.305 |
|
| 2011 |
Clarke R, Shajahan AN, Wang Y, Tyson JJ, Riggins RB, Weiner LM, Bauman WT, Xuan J, Zhang B, Facey C, Aiyer H, Cook K, Hickman FE, Tavassoly I, Verdugo A, et al. Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Hormone Molecular Biology and Clinical Investigation. 5: 35-44. PMID 23930139 DOI: 10.1515/Hmbci.2010.073 |
0.456 |
|
| 2011 |
Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso K, Carabet LA, Song L, Riggins RB, Dakshanamurthy S, Wang Y, Byers SW, Clarke R, et al. G-DOC: a systems medicine platform for personalized oncology. Neoplasia (New York, N.Y.). 13: 771-83. PMID 21969811 DOI: 10.1593/Neo.11806 |
0.316 |
|
| 2011 |
Riggins RB, Heckler MM, Schafer CC, Liu MC. Abstract LB-29: Erk-mediated phosphorylation of the orphan nuclear receptor ERRγ regulates receptor stability and contributes to Tamoxifen resistance in ER+ breast cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-29 |
0.551 |
|
| 2011 |
Hu R, Eltayeb A, Shajahan A, Riggins R, Clarke R. Abstract LB-148: XBP1 regulates NFkappaB signaling in antiestrogen resistant breast cancer cells Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-148 |
0.564 |
|
| 2011 |
Liu M, Dixon J, Xuan J, Riggins R, Chen L, Wang C, Cho Y, Zhu Y, Jin L, Zwart A, Wang M, Klimach U, Wang Y, Renshaw L, Larionov A, et al. S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S1-8 |
0.38 |
|
| 2010 |
Riggins RB, Mazzotta MM, Maniya OZ, Clarke R. Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocrine-Related Cancer. 17: R213-31. PMID 20576803 DOI: 10.1677/Erc-10-0058 |
0.434 |
|
| 2010 |
Ning Y, Riggins RB, Mulla JE, Chung H, Zwart A, Clarke R. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. Molecular Cancer Therapeutics. 9: 1274-85. PMID 20457620 DOI: 10.1158/1535-7163.Mct-09-1169 |
0.476 |
|
| 2010 |
Broustas CG, Ross JS, Yang Q, Sheehan CE, Riggins R, Noone AM, Haddad BR, Seillier-Moiseiwitsch F, Kallakury BV, Haffty BG, Clarke R, Kasid UN. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2939-48. PMID 20400521 DOI: 10.1158/1078-0432.Ccr-09-2351 |
0.432 |
|
| 2010 |
Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 2040-55. PMID 20154269 DOI: 10.1096/Fj.09-138305 |
0.482 |
|
| 2010 |
Crawford AC, Riggins RB, Shajahan AN, Zwart A, Clarke R. Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. Plos One. 5: e8604. PMID 20062536 DOI: 10.1371/Journal.Pone.0008604 |
0.465 |
|
| 2010 |
Cavalli LR, Riggins RB, Wang A, Clarke R, Haddad BR. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Research and Treatment. 121: 227-31. PMID 19697121 DOI: 10.1007/S10549-009-0509-8 |
0.434 |
|
| 2010 |
Ning Y, Riggins RB, Shajahan AN, Zwart A, Clarke R. Abstract 5023: Down-regulating interferon regulatory factor-1 by siRNA promotes endurance to fulvestrant in sensitive breast cancer cells partially via Ras/Raf/MEK/ERK pathway Cancer Research. 70: 5023-5023. DOI: 10.1158/1538-7445.Am10-5023 |
0.458 |
|
| 2010 |
Rechache NS, Riggins RB, Shajahan AN, Zwart A, Clarke R. Abstract 4857: The role of autophagy in taxane resistant breast cancer models Cancer Research. 70: 4857-4857. DOI: 10.1158/1538-7445.Am10-4857 |
0.509 |
|
| 2010 |
Maniya OZ, Zwart A, Chen L, Xuan J, Clarke R, Riggins RB. Abstract 4600: The role of COUP transcription factors in Tamoxifen resistant breast cancer cells Cancer Research. 70: 4600-4600. DOI: 10.1158/1538-7445.Am10-4600 |
0.556 |
|
| 2010 |
Mazzotta MM, Liu MC, Clarke R, Riggins RB. Abstract 4595: ERK/MAPK regulation of ERRγ in Tamoxifen resistant breast cancer Cancer Research. 70: 4595-4595. DOI: 10.1158/1538-7445.Am10-4595 |
0.563 |
|
| 2010 |
Shajahan AN, Riggins RB, Zwart A, Hickman FE, Clarke R. Abstract 2919: XBP1 and the unfolded protein response in antiestrogen resistance in breast cancer Cancer Research. 70: 2919-2919. DOI: 10.1158/1538-7445.Am10-2919 |
0.549 |
|
| 2009 |
Chen L, Xuan J, Wang Y, Hoffman EP, Riggins RB, Clarke R. Identification of condition-specific regulatory modules through multi-level motif and mRNA expression analysis. International Journal of Computational Biology and Drug Design. 2: 1-20. PMID 20054984 DOI: 10.1504/Ijcbdd.2009.027582 |
0.368 |
|
| 2009 |
Shajahan AN, Riggins RB, Clarke R. The role of X-box binding protein-1 in tumorigenicity. Drug News & Perspectives. 22: 241-6. PMID 19609461 DOI: 10.1358/Dnp.2009.22.5.1378631 |
0.419 |
|
| 2009 |
Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y, Zwart A, Nehra R, Liu MC. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 114: 8-20. PMID 19444933 DOI: 10.1016/J.Jsbmb.2008.12.023 |
0.473 |
|
| 2008 |
Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, Clarke R. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Research. 68: 8908-17. PMID 18974135 DOI: 10.1158/0008-5472.Can-08-2669 |
0.533 |
|
| 2007 |
Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, Clarke R. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 4013-27. PMID 17660348 DOI: 10.1096/Fj.06-7990Com |
0.544 |
|
| 2007 |
Schrecengost RS, Riggins RB, Thomas KS, Guerrero MS, Bouton AH. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Research. 67: 6174-82. PMID 17616674 DOI: 10.1158/0008-5472.Can-06-3455 |
0.8 |
|
| 2007 |
Bouker KB, Skaar TC, Harburger DS, Riggins RB, Fernandez DR, Zwart A, Clarke R. The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. Cancer Genetics and Cytogenetics. 175: 61-4. PMID 17498560 DOI: 10.1016/J.Cancergencyto.2006.12.008 |
0.423 |
|
| 2007 |
Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Letters. 256: 1-24. PMID 17475399 DOI: 10.1016/J.Canlet.2007.03.016 |
0.754 |
|
| 2007 |
Rechache N, Riggins R, Zwart A, Clarke R. Molecular mechanisms of taxane resistance The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A419-A |
0.325 |
|
| 2006 |
Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, Bouton AH. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Research. 66: 7007-15. PMID 16849545 DOI: 10.1158/0008-5472.Can-05-3952 |
0.655 |
|
| 2005 |
Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitamins and Hormones. 71: 201-37. PMID 16112269 DOI: 10.1016/S0083-6729(05)71007-4 |
0.727 |
|
| 2005 |
Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, Clarke R. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis. 26: 1527-35. PMID 15878912 DOI: 10.1093/Carcin/Bgi113 |
0.445 |
|
| 2005 |
Riggins RB, Zwart A, Nehra R, Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Molecular Cancer Therapeutics. 4: 33-41. PMID 15657351 |
0.446 |
|
| 2004 |
Hilakivi-Clarke L, Wang C, Kalil M, Riggins R, Pestell RG. Nutritional modulation of the cell cycle and breast cancer Endocrine-Related Cancer. 11: 603-622. PMID 15613442 DOI: 10.1677/Erc.1.00665 |
0.453 |
|
| 2004 |
Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, Clarke R. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Research. 64: 4030-9. PMID 15173018 DOI: 10.1158/0008-5472.Can-03-3602 |
0.478 |
|
| 2003 |
Riggins RB, Quilliam LA, Bouton AH. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. The Journal of Biological Chemistry. 278: 28264-73. PMID 12740391 DOI: 10.1074/Jbc.M303535200 |
0.741 |
|
| 2003 |
Riggins RB, DeBerry RM, Toosarvandani MD, Bouton AH. Src-dependent association of Cas and p85 phosphatidylinositol 3'-kinase in v-crk-transformed cells. Molecular Cancer Research : McR. 1: 428-37. PMID 12692262 |
0.71 |
|
| 2001 |
Bouton AH, Riggins RB, Bruce-Staskal PJ. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene. 20: 6448-58. PMID 11607844 DOI: 10.1038/Sj.Onc.1204785 |
0.721 |
|
| Show low-probability matches. |